Skip to main content
OpenTrials
Completed

NCT Number: NCT00178971

Serotonin 1A Agonists and Cognition in Schizophrenia

Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications. Patients will be assigned to take active medication (Buspar)or placebo along with their prescribed antipsychotic medication for six weeks. Patients' memory and problem-solving ability will be tested before and after medication.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Mental Disorders Psychotic Disorders Schizoaffective Disorder Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Psychiatric Hospital at Vanderbilt

Nashville, Tennessee, 37212, United States

About this study

Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with olanzapine or risperidone for at least three months randomized to receive adjunctive treatment with a 5-HT1A agonist (buspirone, 15-30 mg/day)or placebo.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects must meet all of the following criteria to be eligible for participation in the current research study.

  • Subjects will be males and females between 18-65 years of age;
  • Subjects will have a definite diagnosis by DSM-IV criteria for Schizophrenia or Schizoaffective Disorder;
  • The subjects or their legal guardian must sign the informed consent;
  • Subjects currently being treated with olanzapine or risperidone for a duration of at least 3 months

Exclusion criteria

  • Subjects who are pregnant or lactating
  • Subjects who have brain damage and/or neurological disorders
  • Subjects who have current substance dependence
  • Subjects unable to provide informed consent

Treatment and study plan

adjunctive treatment with buspirone

Drug

buspirone 15-30 mg qd

Placebo

Drug

placebo

Primary outcomes

  1. This study will examine the effect on cognition of the addition of buspirone compared with addition of a sugar pill to patients treated with olanzapine or risperidone

    Time frame: six weeks

Sponsors and collaborators

Lead sponsor

Northwestern University

Other

Collaborators

  • National Alliance for Research on Schizophrenia and Depression

Registry information

Important dates

Study start
2003
Primary completion
2004
Study completion
2004
First posted
Sep 15, 2005
Registry last updated
Jun 7, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.